Stock Report

All about this stock under one free report Last Updated: 19-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Senores Pharmaceuticals Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: SENORES | BSE: 544319

₹1,318.40

up-down-arrow ₹59.60 (4.73%)

As on 16-Oct-2026IST

Market cap

info icon

₹6,058 Cr

Revenue (TTM)

info icon

₹692 Cr

P/E Ratio

info icon

47.9

P/B Ratio

info icon

6.3

Div. Yield

info icon

0 %

Edit peer-selector-edit
Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 6,058 34,586 25,275 16,073 14,003
Revenue (₹ Cr)
 692 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 130.82 1,018.97 497.77 603.02 270.18
Net Margin (%)
 18.13 10.47 20.72 22.63 23.29
RoE (%)
 14.46 21.30 28.49 19.61 14.45
Price to Earnings
 47.94 34.20 50.78 26.65 50.85
Price-To-Book
 6.29 6.61 12.50 4.61 6.75

Income Statement (₹ Cr)

Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
691.72 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
721.39 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
486.96 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
204.76 1,943.92 762.90 836.69 388.38
Depreciation arrow
35.19 425.10 98.11 78.88 74.78
EBIT arrow
169.57 1,518.82 664.79 757.81 313.60
Interest arrow
27.15 148.45 26.33 5.43 0.26
Other Income arrow
29.67 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
172.09 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
41.27 370.94 171.48 197.53 91.39
Profit after Tax arrow
130.82 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
933.60 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
-4.45 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
215.27 723.57 345.47 142.73 50.51
Current Liabilities arrow
424.00 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
1,603.81 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
763.06 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
812.43 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
1,603.81 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
327.09 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
388.43 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
24.43 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
62.05 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-120.56 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
-1.33 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-59.84 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
15.66 25.25 27.50 24.61 18.04
ROE (%) arrow
14.46 21.30 28.49 19.61 14.45
ROA (%) arrow
9.24 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
24.51 15.68 28.03 29.25 28.29
Net Margin (%) arrow
18.13 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
53.57 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
117.98 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
90.67 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
87.05 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
18.71 11.36 22.95 18.43 11.27

Valuation Ratios

 Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
47.94 33.49 50.78 25.81 50.41
Price / Book Value arrow
6.29 6.61 12.50 4.61 6.75
Dividend Yield (%) arrow
0.00 0.20 0.17 0.38 0.56
EV/EBITDA arrow
30.40 18.34 32.92 18.27 34.99
Market Cap (₹ Cr) arrow
3,490.16 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.21 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.03 0.16 -- -- --
Current Ratio arrow
1.92 1.43 2.09 5.21 7.39
Quick Ratio arrow
1.71 0.82 1.37 3.85 5.46
Interest Coverage arrow
7.34 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Senores Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
46.96 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.49 1.09 0.93 0.70 0.52
Receivable days arrow
129.44 88.68 77.32 144.58 169.86
Inventory Days arrow
42.09 84.11 80.83 96.67 97.92
Payable days arrow
218.97 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
-47.43 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...